Ulcerative Colitis - Pipeline Review, H2 2017

Published: Oct, 2017 | Pages: 433 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Pipeline Review, H2 2017, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.

Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 10, 37, 26, 1, 50, 13 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 12 and 1 molecules, respectively.

Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
Introduction 6
Ulcerative Colitis - Overview 7
Ulcerative Colitis - Therapeutics Development 8
Ulcerative Colitis - Therapeutics Assessment 27
Ulcerative Colitis - Companies Involved in Therapeutics Development 41
Ulcerative Colitis - Drug Profiles 83
Ulcerative Colitis - Dormant Projects 397
Ulcerative Colitis - Discontinued Products 404
Ulcerative Colitis - Product Development Milestones 406
Appendix 416

List of Tables

Number of Products under Development for Ulcerative Colitis, H2 2017 24
Number of Products under Development by Companies, H2 2017 26
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 27
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 28
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 29
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 30
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 31
Number of Products under Development by Universities/Institutes, H2 2017 32
Products under Development by Companies, H2 2017 33
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 34
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 35
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 36
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 37
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 38
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 39
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 40
Products under Development by Companies, H2 2017 (Contd..8), H2 2017 41
Products under Development by Universities/Institutes, H2 2017 42
Number of Products by Stage and Target, H2 2017 44
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 45
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 46
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 47
Number of Products by Stage and Mechanism of Action, H2 2017 49
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 50
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 51
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 52
Number of Products by Stage and Route of Administration, H2 2017 54
Number of Products by Stage and Molecule Type, H2 2017 56
Ulcerative Colitis - Pipeline by 4D Pharma PLC, H2 2017 57
Ulcerative Colitis - Pipeline by AbbVie Inc, H2 2017 57
Ulcerative Colitis - Pipeline by AbGenomics International Inc, H2 2017 58
Ulcerative Colitis - Pipeline by Abivax SA, H2 2017 58
Ulcerative Colitis - Pipeline by Adello Biologics LLC, H2 2017 59
Ulcerative Colitis - Pipeline by Aerpio Therapeutics Inc, H2 2017 59
Ulcerative Colitis - Pipeline by Akebia Therapeutics Inc, H2 2017 60
Ulcerative Colitis - Pipeline by Allergan Plc, H2 2017 60
Ulcerative Colitis - Pipeline by Am-Pharma BV, H2 2017 61
Ulcerative Colitis - Pipeline by Amgen Inc, H2 2017 61
Ulcerative Colitis - Pipeline by Aptevo Therapeutics Inc, H2 2017 62
Ulcerative Colitis - Pipeline by Arena Pharmaceuticals Inc, H2 2017 62
Ulcerative Colitis - Pipeline by Atlantic Bio Sci LLC, H2 2017 63
Ulcerative Colitis - Pipeline by Atlantic Healthcare Plc, H2 2017 63
Ulcerative Colitis - Pipeline by Blueberry Therapeutics Ltd, H2 2017 64
Ulcerative Colitis - Pipeline by Boehringer Ingelheim GmbH, H2 2017 64
Ulcerative Colitis - Pipeline by Bristol-Myers Squibb Co, H2 2017 65
Ulcerative Colitis - Pipeline by Celgene Corp, H2 2017 66
Ulcerative Colitis - Pipeline by Celltrion Inc, H2 2017 67
Ulcerative Colitis - Pipeline by ChemoCentryx Inc, H2 2017 67
Ulcerative Colitis - Pipeline by ChironWells GmbH, H2 2017 68
Ulcerative Colitis - Pipeline by Coherus BioSciences Inc, H2 2017 68
Ulcerative Colitis - Pipeline by Cosmo Pharmaceuticals NV, H2 2017 69
Ulcerative Colitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017 69
Ulcerative Colitis - Pipeline by EA Pharma Co Ltd, H2 2017 70
Ulcerative Colitis - Pipeline by Eli Lilly and Co, H2 2017 70
Ulcerative Colitis - Pipeline by Enceladus Pharmaceuticals BV, H2 2017 71
Ulcerative Colitis - Pipeline by Enterome Bioscience SA, H2 2017 71
Ulcerative Colitis - Pipeline by Ferring International Center SA, H2 2017 72
Ulcerative Colitis - Pipeline by Fresenius SE & Co KGaA, H2 2017 72
Ulcerative Colitis - Pipeline by Galapagos NV, H2 2017 73
Ulcerative Colitis - Pipeline by Genentech Inc, H2 2017 73
Ulcerative Colitis - Pipeline by Genor BioPharma Co Ltd, H2 2017 74
Ulcerative Colitis - Pipeline by GlaxoSmithKline Plc, H2 2017 74
Ulcerative Colitis - Pipeline by iCo Therapeutics Inc., H2 2017 75
Ulcerative Colitis - Pipeline by Inception Sciences Inc, H2 2017 75
Ulcerative Colitis - Pipeline by InDex Pharmaceuticals Holding AB, H2 2017 76
Ulcerative Colitis - Pipeline by Innovate Biopharmaceuticals Inc, H2 2017 76
Ulcerative Colitis - Pipeline by Intas Pharmaceuticals Ltd, H2 2017 77
Ulcerative Colitis - Pipeline by Ironwood Pharmaceuticals Inc, H2 2017 77
Ulcerative Colitis - Pipeline by Istesso Ltd, H2 2017 78
Ulcerative Colitis - Pipeline by Johnson & Johnson, H2 2017 78
Ulcerative Colitis - Pipeline by Kaken Pharmaceutical Co Ltd, H2 2017 79
Ulcerative Colitis - Pipeline by Keystone Biologics Inc, H2 2017 79
Ulcerative Colitis - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 80
Ulcerative Colitis - Pipeline by LG Chem Ltd, H2 2017 81
Ulcerative Colitis - Pipeline by LIPID THERAPEUTICS GmbH, H2 2017 81
Ulcerative Colitis - Pipeline by Lycera Corp, H2 2017 82
Ulcerative Colitis - Pipeline by Medestea Research & Production SpA, H2 2017 82
Ulcerative Colitis - Pipeline by Merck & Co Inc, H2 2017 83
Ulcerative Colitis - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017 83
Ulcerative Colitis - Pipeline by Morphotek Inc, H2 2017 84
Ulcerative Colitis - Pipeline by Ogeda SA, H2 2017 84
Ulcerative Colitis - Pipeline by Oncobiologics Inc, H2 2017 85
Ulcerative Colitis - Pipeline by OSE Immunotherapeutics, H2 2017 85
Ulcerative Colitis - Pipeline by Pfizer Inc, H2 2017 86
Ulcerative Colitis - Pipeline by Principia Biopharma Inc, H2 2017 86
Ulcerative Colitis - Pipeline by Protab Ltd, H2 2017 87
Ulcerative Colitis - Pipeline by Protagonist Therapeutics Inc, H2 2017 87
Ulcerative Colitis - Pipeline by Protalix BioTherapeutics Inc, H2 2017 88
Ulcerative Colitis - Pipeline by Qu Biologics Inc, H2 2017 88
Ulcerative Colitis - Pipeline by Re-Pharm Ltd, H2 2017 89
Ulcerative Colitis - Pipeline by Rebiotix Inc, H2 2017 89
Ulcerative Colitis - Pipeline by RedHill Biopharma Ltd, H2 2017 90
Ulcerative Colitis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 90
Ulcerative Colitis - Pipeline by Sareum Holdings Plc, H2 2017 91
Ulcerative Colitis - Pipeline by Seres Therapeutics Inc, H2 2017 91
Ulcerative Colitis - Pipeline by Shire Plc, H2 2017 92
Ulcerative Colitis - Pipeline by Sigmoid Pharma Ltd, H2 2017 92
Ulcerative Colitis - Pipeline by Stelic Institute & Co Inc, H2 2017 93
Ulcerative Colitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2017 93
Ulcerative Colitis - Pipeline by Synergy Pharmaceuticals Inc, H2 2017 93
Ulcerative Colitis - Pipeline by Synlogic Inc, H2 2017 94
Ulcerative Colitis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 94
Ulcerative Colitis - Pipeline by Theravance Biopharma Inc, H2 2017 95
Ulcerative Colitis - Pipeline by Thetis Pharmaceuticals LLC, H2 2017 95
Ulcerative Colitis - Pipeline by Tillotts Pharma AG, H2 2017 96
Ulcerative Colitis - Pipeline by TopiVert Ltd, H2 2017 96
Ulcerative Colitis - Pipeline by TTY Biopharm Company Ltd, H2 2017 97
Ulcerative Colitis - Pipeline by UCB SA, H2 2017 97
Ulcerative Colitis - Pipeline by Ventria Bioscience, H2 2017 98
Ulcerative Colitis - Pipeline by Vivelix Pharmaceuticals Ltd, H2 2017 98
Ulcerative Colitis - Dormant Projects, H2 2017 413
Ulcerative Colitis - Dormant Projects, H2 2017 (Contd..1), H2 2017 414
Ulcerative Colitis - Dormant Projects, H2 2017 (Contd..2), H2 2017 415
Ulcerative Colitis - Dormant Projects, H2 2017 (Contd..3), H2 2017 416
Ulcerative Colitis - Dormant Projects, H2 2017 (Contd..4), H2 2017 417
Ulcerative Colitis - Dormant Projects, H2 2017 (Contd..5), H2 2017 418
Ulcerative Colitis - Dormant Projects, H2 2017 (Contd..6), H2 2017 419
Ulcerative Colitis - Discontinued Products, H2 2017 420
Ulcerative Colitis - Discontinued Products, H2 2017 (Contd..1), H2 2017 421